VISTA Deficiency Exacerbates the Development of Pulmonary Fibrosis by Promoting Th17 Differentiation
Haiping Xie,Xuexin Zhong,Junlin Chen,Shuang Wang,Yuefang Huang,Niansheng Yang
DOI: https://doi.org/10.2147/jir.s458651
IF: 4.5
2024-06-20
Journal of Inflammation Research
Abstract:Haiping Xie, 1, &ast Xuexin Zhong, 1, &ast Junlin Chen, 2 Shuang Wang, 1 Yuefang Huang, 2 Niansheng Yang 1 1 Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China; 2 Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, People's Republic of China &astThese authors contributed equally to this work Correspondence: Niansheng Yang, Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China, Tel +86-20-87755766 ext 8150, Email Background: Interstitial lung disease (ILD), characterized by pulmonary fibrosis (PF), represents the end-stage of various ILDs. The immune system plays an important role in the pathogenesis of PF. V-domain immunoglobulin suppressor of T-cell activation (VISTA) is an immune checkpoint with immune suppressive functions. However, its specific role in the development of PF and the underlying mechanisms remain to be elucidated. Methods: We assessed the expression of VISTA in CD4 T cells from patients with connective tissue disease-related interstitial lung disease (CTD-ILD). Spleen cells from wild-type (WT) or Vsir −/− mice were isolated and induced for cell differentiation in vitro. Additionally, primary lung fibroblasts were isolated and treated with interleukin-17A (IL-17A). Mice were challenged with bleomycin (BLM) following VISTA blockade or Vsir knockout. Moreover, WT or Vsir −/− CD4 T cells were transferred into Rag1 −/− mice, which were then challenged with BLM. Results: VISTA expression was decreased in CD4 T cells from patients with CTD-ILD. Vsir deficiency augmented T-helper 17 (Th17) cell differentiation in vitro. Furthermore, IL-17A enhanced the production of inflammatory cytokines, as well as the differentiation and migration of lung fibroblasts. Both VISTA blockade and knockout of Vsir increased the percentage of IL-17A-producing Th17 cells and promoted BLM-induced PF. In addition, mice receiving Vsir −/− CD4 T cells exhibited a higher percentage of Th17 cells and more severe PF compared to those receiving WT CD4 T cells. Conclusion: These findings demonstrate the significant role of VISTA in modulating the development of PF by controlling Th17 cell differentiation. These insights suggest that targeting VISTA could be a promising therapeutic strategy for PF. Keywords: VISTA, lung fibrosis, Th17 cells, IL-17A, fibroblast Graphical Interstitial lung disease (ILD) is characterized by the involvement of lung interstitium and alveolar spaces, presenting with abnormal proliferation of alveolar wall cells, infiltration of inflammatory cells, and interstitial fibrosis. 1 Pulmonary fibrosis (PF) represents the end-stage of various ILDs, characterized by fibroblast activation, progressive synthesis and deposition of extracellular matrix (ECM), ultimately leading to the destruction of lung architecture. 2 Despite this understanding, the precise mechanisms underlying PF remain unclear. Therefore, a more thorough exploration of PF pathogenesis may reveal novel therapeutic targets for anti-fibrotic treatment. Recently, researchers have uncovered various functions of profibrotic cytokines in the pathogenesis of PF. Interleukin-17A (IL-17A) secreted by T-helper 17 (Th17) cells has been identified as a key promoter of PF development. 3–6 The frequency of IL-17A + CD4 + T cells is expanded in ILD patients. 7,8 In Bleomycin (BLM)-induced PF, IL-17A has been found to enhance neutrophil accumulation and exacerbate PF progression. Conversely, blockade of IL-17A has been shown to alleviate lung inflammation and fibrosis. 6,9,10 Additionally, research has demonstrated that IL-17A enhances collagen synthesis and secretion, promotes epithelial–mesenchymal transition, and suppresses epithelial cell autophagy, all contributing to the exacerbation of PF. 11 Despite these findings, the molecules and specific mechanisms regulating IL-17A secretion by Th17 cells in the context of PF remain elusive, highlighting the need for further research. T cells are involved in PF by secreting numerous profibrotic and inflammatory cytokines, contributing to the subsequent process of fibroblast activation and ECM deposition. 12–14 Immune checkpoints such as PD-1, TIGIT and LAG3 are known to regulate the activation, differentiation and cytokine secretio -Abstract Truncated-
immunology